Advance Program

Transkript

1 Advance Program Program Chairs Thorsten Lewalter, MD, PhD Isar Heart Center, Munich University of Bonn, Bonn, Germany Sanjeev Saksena, MD Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA The Electrophysiology Research Foundation, Warren, NJ, USA

2 MediGuide Technology PROVIDING DIRECTION Navigating Away From Live X-ray MediGuide TM Technology is the first and only solution that enables physicians to navigate devices on pre-recorded X-ray images which allows the physician to reduce the duration of live X-ray during a procedure. MediGuide TM Technology applies 3D visualization and precise navigation to pre-recorded 2D X-ray images, which can be used by the physician to perform complex electrophysiology procedures and CRT implants. Unless otherwise noted, TM indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are registered and unregistered trade marks and service marks of St. J ude Medical, Inc. and its related companies St. Jude Medical, Inc. All rights reserved.

3 Welcome Address Dear Colleagues, We are very pleased to invite you to the Seventh International Symposium for Interventional Electrophysiology which will be held in Munich, Germany, September 18 20, The meeting venue will be the Hotel Hilton Park in Munich. This meeting is being organised by the Isar Heart Center and the Electrophysiology Research Foundation in New Jersey. The symposium will maintain its focus on new technologies, innovative therapy, and new scientific directions in research in the management of cardiac arrhythmias. We are certain that this will be an important and stimulating educational event. The proceedings of the symposium will be published in a special issue of the Journal of Interventional Electrophysiology. We hope you will join the symposium and are looking forward to meet you at the meeting. With warm personal regards, Thorsten Lewalter, MD, PhD Sanjeev Saksena, MD

4 Overall structure and Objectives of Program Focus on advances in basic science and technology, evolving new techniques and therapies in an evidence based world of medicine Wednesday, September 18 4 Featured Workshops complemented by case studies and live cases Objective: Designed to showcase new drugs, technologies and/or teach new antiarrhythmic therapy, complex or new procedures in cardiac rhythm management and cardiology Cardiovascular and Electrophysiology Fellows Course Thursday, September 19 Didactic lectures and interactive discussions Objectives: New directions in basic science and technology with therapeutic impact: Trends in current therapy for the practicing cardiologist and EP Sessions: I, II, III, IV Basic science and Pharmacology New Technology _ Atrial Fibrillation: Pharmacology and Clinical trials of Anticaogulants _ Pacing & ICD Therapy: New technology (wireless devices and MRI safe devices and leads, applications of remote monitoring, current Registries and clinical trials) Ventricular Fibrillation and Sudden Death Friday, September 20 Objectives: Integrating advances in basic science and technology into an evidence based world Sessions: V, VI, VII Catheter ablation: clinical trials Heart failure clinical trials Outcomes and Clinical Trials in Electrophysiology and Pacing

5 PROGRAM DAY 1 Wednesday, September 18

6 PROGRAM DAY 1 Wednesday, September 18 Workshop 1: Imaging, Mapping and Navigation in the EP Lab New Techniques and How to Apply Them (An Interactive faculty-audience workshop) 8:00 10:00 Co Chairs: Klaus Tiemann / Balbir Singh 8:00 8:20 Intracardiac Echocardiography: How to perform ICE guided CRT & LAA imaging from new imaging windows Sanjeev Saksena 8:20 8:40 Cardiac MRI and Cardiac CT: How to integrate into the EP Lab Klaus Tiemann 8:40 9:00 Case Demonstration: Role of 3D TEE to guide interventional procedures Klaus Tiemann 9:00 9:20 Case Demonstration: CT reconstruction of LAA morphologies Andrea Natale 9:20 9:40 Case Demonstration: How to perform rotor mapping the TOPERA technique: Sanjiv Narayan 9:40 10:00 Case Demonstration: Highdensity mapping of Atrial tachycardia the RHYTHMIA experience Josef Kautzner 10:00 10:20 Mapping and Ablation of VF: How and For Whom Stephan Willems 10:30 11:00 Coffee Break 11:00 12:30 Co-Chairs: Johannes Brachmann / Sanjeev Saksena 11:00 11:20 New techniques for Robotic Navigation in AF Andrea Natale 11:20 11:40 Robotic Navigation with the Hansen system: Learning curves and lessons learned Werner Jung 11:40 12:00 Case Demonstration: VF Ablation using Stereotaxis magnetic robotic navigation system Georg Nölker 12:00 12:15 Case Demonstration: The Mediguide Mapping & Ablation Experience Gerhard Hindricks 12:15 12:30 Case Demonstration: Catheter Ablation using the Amigo Robotic Navigation system using an open architecture ablation catheter concept Leif-Hendrik Boldt 12:30 13:30 Lunch

7 PROGRAM DAY 1 Wednesday, September 18 Workshop 2: New Directions in Antiarrhythmic Therapy and Stroke Prevention 8:00 10:00 Co-Chairs: Eckhard Alt / Dobromir Dobrev 8:00 8:30 Dronedarone: guideline position and current clinical use Andreas Goette 8:30 9:00 New Targets for Antiarrhythmic Drug Therapy: Atrial specific agents and substrate modifiers tbd 9:00 9:30 MicroRNA and atrial fibrillation: biomarker or therapeutic target? tbd 9:30 10:00 Fundamentals of cardiac regeneration and repair Eckhard Alt 10:00 10:30 Coffee Break 10:30 12:30 Co-Chairs: Michael Ezekowitz / Ernst Vester 10:30 11:00 Second Generation NOACs: Pharmacology and Clinical Trials Michael Ezekowitz 11:00 11:20 Cardioversion of Atrial Fibrillation: Is Dabigatran preferable to Warfarin The RE-LY Experience: Rangadham Nagarakanti 11:20 11:45 Factor X inhibitors Rivaroxaban and Apixaban: Clinical trials and application Ernst Vester 11:45 12:00 Clinical Indication for left atrial appendage occlusion Thorsten Lewalter 12:00 12:15 Case Demonstration: Amplatzer device implantation Thorsten Lewalter 12:15 12:30 Panel Discussion 12:30 13:30 Lunch

8 PROGRAM DAY 1 Wednesday, September 18 Workshop 3: Advanced Catheter Ablation in AF and VT/VF New Technologies and Intervention Targets 13:30 16:45 Co-Chairs: Andrea Natale / Gerhard Hindricks 13:30 14:00 State of the Art lecture : Established and Upcoming Technology for PV Disconnection Andrea Natale 14:00 14:15 Case Demonstration: Cryo Balloon Technology Uwe Dorwarth 14:15 14:30 Case Demonstration: Endoscopic Laser Balloon Ablation Thorsten Lewalter 14:30 14:45 Panel Discussion 14:45 15:15 Coffee Break 15:15 15:45 State of the Art lecture : Substrate Identification and Ablation Strategy in persistent AF Michel Haissaguerre 15:45 16:00 Case Demonstration: Ablation of Human AF Rotors Sanjiv Narayan 16:00 16:15 Case Demonstration: Ablation of CFAE s Isabell Deisenhofer 16:15 16:30 Case Demonstration: Hybrid therapy for AF treatment Sanjeev Saksena 16:30 16:45 Panel Discussion 16:45 18:00 Co-Chairs: Raj Kaushik / Thorsten Hanke 16:45 17:15 State of the Art lecture : Ablation in persistent AF the surgeons perspective Nico Doll 17:15 17:30 Case Demonstration: Endoscopic Surgical AF Ablation as part of a hybrid strategy Stephen Wildhirt 17:30 17:45 Case Demonstration: Stand alone surgical AF ablation Nico Doll 17:45 18:00 Case Demonstration: Relevance of continous AF monitoring Thorsten Hanke 18:00 Wrap-Up 8

9 PROGRAM DAY 1 Wednesday, September 18 Workshop 4: New Devices for Rhythm Monitoring, Bradycardia, Heart Failure and Hypertension 13:30 14:45 Co-Chairs: Gerhard Steinbeck / Sanjeev Saksena 13:30 14:00 Renal Denervation New Tools and new applications Thomas Schmitz 14:00 14:15 Case Demonstration: The EnligHTN denervation system Thomas Schmitz 14:15 14:30 Lead Extraction Raj Kaushik 14:30 14:45 Practical Experience with MRI Safe Devices: Werner Jung 14:45 15:15 Coffee Break 15:15 17:00 Co-Chairs: Kamal Sethi / Andreas Goette 15:15 15:45 Clinical Experience with Subcutaneous defibrillator Riccardo Cappato 15:45 16:10 Wireless Telemetry and Remote Monitoring of ICDs/CRT s: Practical implementation and environmental interactions: Stefan Sack 16:10 16:30 Bridge therapy in Defibrillation Increasing role of the LIFEVEST concept Helmut Klein 16:30 16:45 Case Demonstration: Subcutaneous ICD implantation Riccardo Cappato 16:45 17:00 Case Demonstration: Intraoperative Optimization of CRT with ICE Sanjeev Saksena 17:45 18:00 Panel Discussion and Wrap-Up 9

10 Kann man Schlaganfall- Prophylaxe bei Vorhofflimmern deutlich vereinfachen? 1 x 1 täglich Fortschritt von Bayer. Xarelto 15 mg / 20 mg Filmtabletten Wirkstoff: Rivaroxaban. Vor Verschreibung Fachinformation beachten. Zusammensetzung: Wirkstoff: 15 mg / 20 mg Rivaroxaban. Sonstige Bestandteile: Mikrokristalline Cellulose, Croscarmellose-Natrium, Lactose-Monohydrat, Hypromellose, Natriumdodecylsulfat, Magnesiumstearat, Macrogol (3350), Titanoxid (E171), Eisen(III)oxid (E172). Anwendungsgebiete: Prophylaxe von Schlaganfällen und systemischen Embolien bei erwachsenen Patienten mit nichtvalvulärem Vorhofflimmern und einem oder mehreren Risikofaktoren, wie kongestiver Herzinsuffizienz, Hypertonie, Alter ab 75 Jahren, Diabetes mellitus, Schlaganfall oder transitorischer ischämischer Attacke in der Anamnese. Behandlung von tiefen Venenthrombosen (TVT) und Lungenembolien (LE) sowie Prophylaxe von rezidivierenden TVT und LE bei Erwachsenen. Gegenanzeigen: Überempfindlichkeit gegen Rivaroxaban oder einen d. sonst. Bestandteile; klinisch relevante akute Blutungen; Läsionen oder Situationen mit einem signifikanten Risiko einer schweren Blutung; gleichzeitige Anwendung von anderen Antikoagulanzien außer bei der Umstellung der Antikoagulationstherapie auf oder von Rivaroxaban oder wenn unfrakt. Heparin in Dosen gegeben wird, die notwendig sind, um die Durchgängigkeit eines zentralvenösen oder arteriellen Katheters zu erhalten; Lebererkrankungen, die mit einer Koagulopathie u. einem klinisch relevanten Blutungsrisiko, einschließlich zirrhotischer Patienten mit Child Pugh B und C, verbunden sind; Schwangerschaft u. Stillzeit. Vorsichtsmaßnahmen und Warnhinweise: Eine klinische Überwachung in Übereinstimmung mit der antikoagulatorischen Praxis wird während der gesamten Behandlungsdauer empfohlen. Die Gabe von Xarelto sollte bei Auftreten einer schweren Blutung unterbrochen werden. Die Anwendung von Rivaroxaban wird nicht empfohlen bei Patienten: - mit einer schweren Nierenfunktionseinschränkung (Kreatinin-Clearance < 15 ml/min), - die zeitgleich eine systemische Behandlung mit Wirkstoffen, die gleichzeitig stark CYP3A4 und P-gp inhibieren, z. B. Azol-Antimykotika oder HIV-Proteaseinhibitoren, erhalten, - mit einem erhöhten Blutungsrisiko und, da keine Daten vorliegen, bei Patienten: - unter 18 Jahren, - mit künstlichen Herzklappen, - mit einer LE, die hämodynamisch instabil sind oder eine Thrombolyse oder pulmonale Embolektomie benötigen, - die zeitgleich mit Dronedaron behandelt werden. Die Anwendung sollte mit Vorsicht erfolgen bei Patienten: - mit erhöhtem Blutungsrisiko, - mit einer schweren Nierenfunktionsstörung (Kreatinin-Clearance ml/min), - mit einer Nierenfunktionsstörung, wenn gleichzeitig andere Arzneimittel eingenommen werden, die zu erhöhten Rivaroxaban Plasmaspiegeln führen, - die gleichzeitig auf die Gerinnung wirkende Arzneimittel erhalten, - die gleichzeitig starke CYP3A4 Induktoren erhalten. Bei Patienten mit dem Risiko einer ulzerativen gastrointestinalen Erkrankung kann eine prophylaktische Behandlung erwogen werden. Obwohl die Behandlung mit Rivaroxaban keine Routineüberwachung der Exposition erfordert, können die mit einem kalibrierten quantitativen Anti-Faktor Xa-Test bestimmten Rivaroxaban-Spiegel in Ausnahmesituationen hilfreich sein. Für Patienten mit einer mittelschweren oder schweren Nierenfunktionsstörung sowie für Patienten mit einer TVT/LE, deren abgeschätztes Blutungsrisiko überwiegt, gelten spezielle Dosisempfehlungen. Xarelto enthält Lactose. Nebenwirkungen: Häufig: Anämie, Schwindel, Kopfschmerzen, Augeneinblutungen, Hypotonie,Hämatome, Epistaxis, Hämoptyse, Zahnfleischbluten, gastrointestinale Blutungen, gastrointestinale u. abdominale Schmerzen, Dyspepsie, Übelkeit, Verstopfung, Durchfall, Erbrechen, Pruritus, Hautrötung, Ekchymose, kutane und subkutane Blutung, Schmerzen in den Extremitäten, Blutungen im Urogenitaltrakt, Nierenfunktionseinschränkung, Fieber, periphere Ödeme, verminderte Leistungsfähigkeit, Transaminasenanstieg, postoperative Blutungen,Bluterguss, Wundsekretion. Gelegentlich: Thrombozythämie, allergische Reaktion, allergische Dermatitis, zerebrale und intrakranielle Blutungen, Synkope, Tachykardie, trockener Mund, Leberfunktionsstörung, Urtikaria, Hämarthros, Unwohlsein, Anstieg von: Bilirubin, alkalischer Phosphatase im Blut, LDH, Lipase, Amylase, GGT. Selten: Gelbsucht, Blutung in einen Muskel, lokale Ödeme, Anstieg von konjugiertem Bilirubin, vaskuläres Pseudoaneurysma (gelegentlich beobachtet bei der Präventionstherapie nach einem ACS nach perkutaner Intervention). Häufigkeit nicht bekannt: Kompartmentsyndrom oder (akutes) Nierenversagen als Folge einer Blutung. Verschreibungspflichtig. Stand: DE/3; 08/2013 Bayer Pharma AG, Berlin, Deutschland L.DE.GM

11 PROGRAM DAY 2 Thursday, September 19

12 PROGRAM DAY 2 Thursday, September 19 8:00 8:10 Welcome Thorsten Lewalter / Sanjeev Saksena 8:10 9:00 Opening Plenary Session Interventional EP: Past, Present and Future Co-Chairs: John Camm / Gerald Naccarelli 8:10 8:25 Introduction: Symposium on Interventional Electrophysiology: Thorsten Lewalter / Berndt Lüderitz 8:25 8:45 Welcome Adress tbd 8:45 9:00 Keynote Lecture: Thromboembolic risk in Interventional Electrophysiology Practice: Recent Advances in Diagnosis and Management Michael Ezekowitz 9:00 10:40 Session I: Advances in Basic Science and Regenerative Medicine Co-Chairs: Stefan Kääb / Dobromir Dobrev 9:00 9:30 Genetics in AF Current Understanding Arne Pfeufer 9:30 10:00 The Atrial Substrate and Novel molecular targets for AF therapy Dobromir Dobrev 10:00 10:30 Stem Cell Therapy for Heart Disease: Current Clinical Status Martin Bergmann 10:30 11:00 Coffee Break 11:00 13:00 Session II: New Technologies in Catheter Ablation Co-Chairs: Sanjeev Saksena/ Stephan Willems 11:00 11:30 Mediguide Impact on Catheter Ablation Techniques and Workflow Dhanunjay Lakireddy 11:30 12:00 Stereotactic and Robotic Systems for Catheter Manipulation Georg Nölker 12

13 PROGRAM DAY 2 Thursday, September 19 12:00 12:30 Endoscopic Ablation Systems Thorsten Lewalter 12:30 13:00 Contact force measurement the final missing link in catheter ablation? tbd 13:00 14:00 Lunch 14:00 15:50 Session III: Atrial Fibrillation: Pharmacology and Clinical trials of Anticaogulants Co-Chairs: Gerhard Steinbeck / Franz Goss 14:00 14:20 Clinical Trials with Atrial Specific Agents Dobromir Dobrev 14:20 14:40 RAAS Inhibitors and Fish Oils: Do They Have a Role in Preventing AF? Gerald Naccarelli 14:40 15:00 Newer antithrombotics and their antidotes: current status Sam Lévy 15:00 15:30 Keynote Lecture: Guidelines for antiarrhythmic and anticoagulant therapy: Trial evidence versus Post marketing Surveillance A. John Camm 15:30 15:50 Panel Discussion 15:50 16:15 Coffee Break 16:15-18:00 Session IV: Pacing and Defibrillation Co-Chairs: Sanjeev Saksena/ Berndt Lüderitz 16:15 17:10 Left ventricular or biventricular pacing? Single or multielectrode leads? An implanter s viewpoint Kamal Sethi 17:10 17:30 ICE guided cardiac resynchronization therapy and the CHOICE trial April Slee 17:30 17:50 Subcutaneous defibrillator: clinical evidence and current practice Riccardo Cappato 17:50 18:10 Reverse remodeling of the left atrium with dual site right atrial pacing Randy Nagarakanti 18:10 18:30 Panel Discussion 13

14 [ ] I WEAR IT BECAUSE... I m the only babysitter they trust. Prescribe it to protect her from sudden cardiac arrest. She will wear it for so many other reasons. LifeVest median daily use is 94% or 22.6 hours per day1 Patients feel more confident returning to their normal daily activities when wearing the LifeVest2 LifeVest patients don t worry as much because they know the LifeVest is protecting them2 +49 (0) ZOLL Medical Corporation. All rights reserved. ZOLL and LifeVest are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. 1 ZOLL. Patient Use, Indications, and Coverage. February Available at Accessed February 28, The Journal of Innovations in Cardiac Rhythm Management, March 2012: C0162revFI

15 PROGRAM DAY 3 Friday, September 20

16 PROGRAM DAY 3 Friday, September 20 8:00 9:45 Session V: Catheter ablation and Treatment strategies in VT and Atrial Fibrillation: clinical trials Co-Chairs: Gerald Naccarelli / Riccardo Cappato 8:00 8:20 Concepts and Current Trial Status of VT ablation in Structural Heart Disease Balbir Singh 8:20 8:40 Dronedarone Trial status and perspective Gerald Naccarelli 8:40 9:00 FREEZE and Fire&ICE: Is the Cryo-Ballon hot? Ellen Hoffmann 9:00 9:20 Is Mortality the key outcome for AF therapy trials? Sanjeev Saksena 9:20 9:40 Cryptogenic Stroke The CRYSTAL AF Study Johannes Brachmann 9:40 11:00 Session VI: Heart failure clinical trials Co-Chairs: Ellen Hoffmann / Kamal Sethi 9:40 10:00 Remote Heart Failure Monitoring in Device Patients Stefan Sack 10:00 10:20 New Sensor Technology for HF in Clinical Trials Werner Jung 10:20 11:00 CASTLE-AF: Is there an AF-HF dialogue? Johannes Brachmann 10:45 11:00 Panel Discussion 11:00 11:15 Coffee Break 11:15 13:00 Session VII: Outcomes and Clinical Trials Co-Chairs: Thorsten Lewalter / Sanjeev Saksena 11:15 11:45 Key Note Lecture: History of Oral Anticoagulation Berndt Lüderitz 11:45 12:05 ICD Lead registries and prospective clinical trials: the view in 2013 Dhanunjay Lakireddy 12:05 12:25 Sillent stroke in catheter ablation procedures: outcomes and clinical trials Thomas Deneke 12:25 12:55 Periprocedural anticoagulation with dabigatran, rivaroxaban and apixaban Sam Lévy 12:55 13:00 Closing Remarks Sanjeev Saksena 13:00 15:00 Farewell Buffet 16

17 Course Directors Thorsten Lewalter Sanjeev Saksena International Faculty Martin Bergmann, Hamburg, DE Leif-Hendrik Boldt, Berlin, DE Johannes Brachmann, Coburg, DE A. John Camm, London, GB Riccardo Cappato, Milan, IT Isabell Deisenhofer, Munich, DE Thomas Deneke, Bad Neustadt, DE Dobromir Dobrev, Essen, DE Uwe Dorwarth, Munich, DE Nico Doll, Stuttgart, DE Michael Ezekowitz, Wynnewood, PA, US Andreas Goette, Paderborn, DE Franz Goss, Munich, DE Michel Haissaguerre, Bordeaux, FR Thorsten Hanke, Lübeck, DE Gerhard Hindricks, Leipzig, DE Ellen Hoffman, Munich, DE Werner Jung, Villingen, DE Stefan Kääb, Munich, DE Josef Kautzner, Prague, CZ Raj Kaushik, Passaic, NJ, US Helmut Klein, Munich, DE Dhanunjay Lakireddy, Kansas City, KS, US Sam Levy, Marseille, FR Thorsten Lewalter, Munich, DE Berndt Lüderitz, Bonn, DE Gerald Naccarelli, Hershey, PA, US Randy Nagarakanti, New Orleans, LA, US Sanjiv Narayan, San Diego, CA, US Andrea Natale, Austin, TX, US Georg Nölker, Bad Oeynhausen, DE Arne Pfeufer, Munich, DE Stefan Sack, Munich, DE Sanjeev Saksena, New Brunswick, NJ, US Thomas Schmitz, Essen, DE Kamal Sethi, New Delhi, IN Balbir Singh, New Delhi, IN April Slee, MS, Warren, NJ, US Gerhard Steinbeck, Munich, DE Klaus Tiemann, Munich, DE Ernst Vester, Duesseldorf, DE Reza Wakili, Munich, DE Stephen Wildhirt, Munich, DE Stephan Willems, Hamburg, DE 17

18 German Cardiac Society Organized by Isar Heart Center, Munich / Germany The Electrophysiology Research Foundation, Warren / NJ, USA Endorsed by For additional information contact program coordinators: Paula Cardona (United States) Phone: Fax: eprf@aol.com Daniela Lutz (Europe) Phone: Fax: daniela.lutz@isarkliniken.de The German Cardiac Society Bundesverband Niedergelassener Kardiologen e. V. (BNK) 18

19 Platinum Sponsor Gold Sponsors BIOTRONIK Silver Sponsors Bronze Sponsors 3.000,- EUR 19

20 Symposium Information Venue: Hilton Munich Park Hotel Am Tucherpark München Germany Date: September 18 20, 2013 Official language: English Accreditation: The symposium is accredited by the Bayerische Landesaerztekammer. Registration and accomodation: Could be made via the electronic form placed on the symposium website Registration fees: Days Fellows Regular Day 1 50,- 75,- Day ,- 90,- All Days 90,- 125,- Hotelreservation for Hilton Munich Park by KORESE Convention & Event Service GmbH Jochen Geiger Kornhausgasse Ravensburg Germany Phone: Fax: geiger@korese.com Website: